Quest Pharmatech Inc V.QPT

Interesting

[ARIMA11]

https://canariabio.com/eng/rnd/pipeline.php
Still alot of phase II ongoing.

Also this in the last meaningful release.

https://ceo.ca/@newswire/oregovomab-phase-iii-clinical-study-fails-futility
The DSMB also expressed the opinion that due to the characteristics of immunotherapy drugs, there is a possibility of significant efficacy in overall survival and recommended that follow up observations be continued in study subjects.

QPT is sadly not in control, unbelievable how these guys messed up this deal.
Took paper money instead or real money. Unbelievable how bad this is..

[ARIMA11]

https://www.hepalink.com/en/MedicineBusiness/index.aspx https://www.hepalink.com/OncoVent/en/oreg.html Worth keeping an eye on this...

[TrickyGame]

I believe QPT has said they are willing to go to court to protect thier 45% interest in oregovomab. At best they end up getting Carariabio bonds and shares as payment for theier interest in oregovomab and the company does well. At worst the company goes to court to protect thier interest and wins and gets either cash and/or canariabio bonds and shares as payment for their interest in oregovomab

[ARIMA11]

Not sure if tQPT have the funds for a lenghty legal battle with Canaribio in court. QPT have little revenues. Hoping that Canaribio will eventually provide some money (cash) which would help. Frankly this situation QPT put themselves in could have been avoided with proper negotiations

[TrickyGame]

With $300 million deal that was done wrong denying QPT the cash for their 45% interest in oregovomab and that same 45% interest in oregovomab's potential sales I'm sure QPT will be able to find a law firm that will take the case for a fee only if they win

[G1945V]

Let the Clinical Trial play out. Canaribio is on the hook no matter what. Let's hope Phase 111 succeeds. If it doesn't, Oregovomab would be worthless. Madiyalakan the CEO of both QPT & OncoQuest Inc. knows he is in no position financially to conduct the Trial. He is gambling that Canaribio may have some success.  Sueing for the IP is not in the cards as things stand. Even if we

[G1945V]

In addition to the above, I highly doubt Shenzhen Hepalink a 15% owner of QPT will let Canaribio run away with Oregovomab unchallenged if that is where their intentions lie. Hepalink, our poison pill, our protector, surely has bigger muscles than Canaribio. I am sure Hepalink is counting on the success of  Oregovomab. https://www.hepalink.com/en/MedicineBusiness/index.aspx jmo G1945V